[1]张晓培,姚进.阿达木单抗应用于非感染性葡萄膜炎的治疗研究现状[J].眼科新进展,2021,41(3):286-289.[doi:10.13389/j.cnki.rao.2021.0060]
　ZHANG Xiaopei,YAO Jin.Research status of adalimumab in non-infectious uveitis[J].Recent Advances in Ophthalmology,2021,41(3):286-289.[doi:10.13389/j.cnki.rao.2021.0060]
点击复制

阿达木单抗应用于非感染性葡萄膜炎的治疗研究现状/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
41卷
期数:
2021年3期
页码:
286-289
栏目:
文献综述
出版日期:
2021-03-05

文章信息/Info

Title:
Research status of adalimumab in non-infectious uveitis
作者:
张晓培; 姚进
210000　江苏省南京市，南京医科大学附属眼科医院
Author(s):
ZHANG Xiaopei; YAO Jin
The Affiliated Eye Hospital of Nanjing Medical University，Nanjing 210000，Jiangsu Province，China
关键词:
阿达木单抗; 肿瘤坏死因子-α; 非感染性葡萄膜炎
Keywords:
adalimumab;  tumor necrosis factor alpha;  non-infectious uveitis
分类号:
R773
DOI:
10.13389/j.cnki.rao.2021.0060
文献标志码:
A
摘要:
阿达木单抗（adalimumab,ADA)是一种抗肿瘤坏死因子-α(TNF-α)的重组 IgG1，是完全人源化的单克隆抗体，对可溶性及膜性TNF-α有高度亲和性，并能与之特异性结合。非感染性葡萄膜炎是指除外感染因素及伪装综合征等的一类炎症性眼病，常累及葡萄膜、视网膜、视网膜血管及玻璃体，其发病率及致盲率均较高。近年来，ADA在非感染性葡萄膜炎治疗方面的有效性、持续性以及安全性已被初步证实。本文就ADA在非感染性葡萄膜炎治疗中的研究现状展开综述。
Abstract:
Adalimumab is an anti-tumor necrosis factor alpha (TNF-α) recombinant IgG1, a fully humanized monoclonal antibody binding soluble human (TNF-α) with high affinity and specificity. Non-infectious uveitis refers to a type of inflammatory eye disease that excludes infection factors and camouflage syndrome, and often involves the uvea, retina, retinal blood vessels and vitreous, and its morbidity and blindness rate are both high. Recently, the effectiveness, continuity, and safety of adalimumab in the treatment of non-infectious uveitis have been initially confirmed. This article reviews the research status of adalimumab in non-infectious uveitis.

参考文献/References:

［1］　杨培增.葡萄膜炎的研究进展［J］.中华眼科杂志,2005,41(12):1149-1152.
YANG P Z.Research progress of uveitis［J］.Chin J Ophthalmol,2005,41(12):1149-1152.
［2］　AIRODY A,HEATH G,LIGHTMAN S,GALE R.Non-infectious uveitis:optimising the therapeutic response［J］.Drugs,2016,76(1):27-39.
［3］　ZHAO C,ZHANG M.Immunosuppressive treatment of non-infectious uveitis:history and current choices［J］.Chin Med Sci J,2017,32 (1):48-61.
［4］　GMEZ-GMEZ A,LOZA E,ROSARIO M P,ESPINOSA G,MORALES J M G R,HERRERAS J M,et al.Efficacy and safety of immunomodulatory drugs in patients with anterior uveitis:A systematic literature review［J］.Medicine (Baltimore),2017,96(42):e8045.
［5］　黄世杰.FDA批准阿达木单抗治疗眼葡萄膜炎［J］.国际药学研究杂志,2016,43(5):997.
HUANG S J.FDA approves Adalimumab for the treatment of uveitis［J］.Int J Pharm Res,2016,43(5):997.
［6］　HALE S,LIGHTMAN S.Anti-TNF therapies in the management of acute and chronic uveitis［J］.Cytokine,2006,33:231-237.
［7］　DICK A D,FORRESTER J V,LIVERSIDGE J,COPE A P.The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU)［J］.Prog Retin Eye Res,2004,23:617-637.
［8］　CERNOW S J,FALCIANI F,DURRANI O M,CHEUNG C M,ROSS E J,WLOKA K,et al.Multiplex bead immunoassay analysis of aqueous humor reveals distinct cytokine profiles in uveitis［J］.Invest Ophthalmol Vis Sci,2005,46(11):4251-4259.
［9］　TRACEY D,KLARESKOG L,SASSO E H,SALFEID J G,TAK P P.Tumor necrosis factor antagonist mechanisms of action:a comprehensive review［J］.Pharmacol Ther,2008,117(2):244-279.
［10］　FELDMANN M.Development of anti-TNF therapy for rheumatoid arthritis［J］.Nat Rev Immunol,2002,2(5):364-371.
［11］　MO J S,MATSUKAWA A,OHKAWARA S,YOSHINAGA M.Involvement of TNF alpha,IL-1 beta and IL-1 receptor antagonist in LPS-induced rabbit uveitis［J］.Exp Eye Res,1998,66(5):547-557.
［12］　COUTO C,SCHLAEN A,FRICK M,KHOURY M,LOPEZ M,HURTADO E,et al.Adalimumab treatment in patients with Vogt-Koyanagi-Harada disease［J］.Ocul Immunol Inflamm,2018,26(3):485-489.
［13］　SCHUSTER L,SAUTER M,UHI P,MEID A,HAEFELI W E,WEISS J,et al.Reporter cell assay-based functional quantification of TNF-α- antagonists in serum-a proof-of-principle study for adalimumab［J］.Anal Biochem,2020,26(2):113646.
［14］　GREBE K M,SALFELD J,KAYMAKCALAN Z.Lack of adalimumab’s complement dependent cytotoxicity on human cells expressing complement regulatory proteins［J］.J Transl Med,2010,8(Suppl 1):9.
［15］　FLORES-ROBLES B J,BLANCO-MADRIGAL J,SANABRIA-SANCHINEL A A,PASCUAL D H,DEMETROI-PABLO R,BLANCO R.Anti-TNFα therapy and switching in severe uveitis related to Vogt-Koyanagi-Harada syndrome［J］.Eur J Rheumatol,2017,4(3):226-228.
［16］　TAKAYAMA K,OBATA H,TAKEUCHI M.Efficacy of adalimumab for chronic Vogt-Koyanagi-Harada disease refractory to conventional corticosteroids and immunosuppressive therapy and complicated by central serous chorioretinopathy［J］.Ocul Immunol Inflamm,2019,28(3):509-512.
［17］　KWON H Y,WOO S J.A Case of recurrent vogt-koyanagi-harada disease successfully treated with adalimumab in young female adult patient［J］.Korean J Ophthalmol,2020,34(1):92-93.
［18］　BENY F,FARKAS A,HORVTH H,NAGY Z Z,SZEPESSY Z.Systemic biological treatment in ophthalmology［J］.Orv Hetil,2019,160(44):1744-1750.
［19］　STREET D,SIVAGURU A,SREEKANTAM S,MOLLAN S P.Vogt-Koyanagi-Harada disease［J］.Pract Neurol,2019,19(4):364-367.
［20］　SU E,OZA V S,LATKANY P.A case of recalcitrant pediatric Vogt-Koyanagi-Harada disease successfully controlled with adalimumab［J］.J Formos Med Assoc,2019,118(5):945-950.
［21］　JEROUDI A,ANGELES-HAN S T,YEH S.Efficacy of adalimumab for pediatric Vogt-Koyanagi-Harada syndrome［J］.Ophthalmic Surg Lasers Imaging Retina,2014,45(4):332-334.
［22］　ONO T,IWASAKI T,TERADA Y,ABE K,LEE J,MOCHIZUKI M,et al.Serum KL-6 elevation in a uveitis patient with Behet’s disease treated with adalimumab［J］.Am J Ophthalmol Case Rep,2020,18:100660.
［23］　SILVESTRI E,BITISSI A,BETTIOL A,EMMI G,URBAN M L,MATTIOLI I,et al.Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases:focus on Behet’s syndrome［J］.Inflammopharmacology,2020,28(3):711-718.
［24］　PIRANI V,PELLICCIONI P,DE TURRIS S,ROSATI A,FRANCESCHI A,PASANISI P,et al.Intraocular inflammation control and changes in retinal and choroidal architecture in refractory non-infectious uveitis patients after adalimumab therapy［J］.Clin Med,2020,9(2):pii:E510.
［25］　LAKRA R,SHAH A,KAUSHIK V,BISWAS J,DUTTA MAJUMDER P.Use of anti-tumour necrosis factor-alpha agents in the management of HLA-B-27-associated uveitis:The first case series from India［J］.Ocul Immunol Inflamm,2020,14:1-5.
［26］　HATEMI G,SEYAHI E,FRESKO I,TALARICO R,HAMURYUDAN V.One year in review 2019:Behet’s syndrome［J］.Clin Exp Rheumatol,2019,121(6):3-17.
［27］　CORDERO-COMA M,YILMAZ T,ONAL S.Systematic review of anti-tumor necrosis factor-alpha therapy for treatment of immune-mediated uveitis［J］.Ocul Immunol Inflamm,2013,21(1):19-27.
［28］　JAFFE G J,DICK A D,BREZIN A P,NGUYEN Q D,THORNE J E,KESTELYN P,et al.Adalimumab in patients with active noninfectious uveitis［J］.N Engl J Med,2016,375:932-943.
［29］　NGUYEN Q D,MERRILL P T,JAFFE G J,DICK A D,KURUP S K,SHEPPARD J,et al.Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL Ⅱ):a multicentre,double-masked,randomised,placebo-controlled phase 3 trial［J］.Lancet,2016,388:1183-1192.
［30］　SUHLER E B,ADAN A,BREZIN A P,FORTIN E,GOTO H,JAFFE G J,et al.Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study:VISUAL Ⅲ［J］.Ophthalmology,2018,125:1075-1087.
［31］　TUGAL-TUTKUN I,ONAL S,ALTAN-YAYCIOGLU R,HUSEYIN ALTUNBAS H,URGANCIOGLU M.Uveitis in Behqet disease:an analysis of 880 patients［J］.Am J Ophthalmol,2004,138(3):373-380.
［32］　DEUTER C M,KTTER I,WALLACE G R,MURRAY P I,STBIGER N,ZIERHUT M.Behet’s disease:ocular effects and treatment［J］.Prog Retin Eye Res,2008,27(1):111-136.
［33］　MESQUIDA M,MOLINS B,LLORENQ V,HERNNDEZ M V,ESPINOSA G,DICK A D,et al.Current and future treatments for Behet’s uveitis：road to remission［J］.Int Ophthalmol,2014,34(2):365-381.
［34］　EL-ASRAR A M,STRUYF S,KANGAVE D,AL-OBEIDAN S S,OPDENAKKER G,GEBOES K,et al.Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis［J］.Clin Immunol,2011,139:177-184.
［35］　AHN J K,YU H G,CHUNG H,PARK Y G.Intraocular cytokine environment in active Behet’s uveitis［J］.Am J Ophthalmol,2006,142:429-434.
［36］　INTERLANDI E,LECCESE P,OLIVIERI I,LATANZA L.Adalimumab for treatment of severe Behet’s uveitis:a retrospective long-term follow-up study［J］.Clin Exp Rheumatol,2014,32:S58-S62.
［37］　FABIANI C,VITALE A,EMMI G,VANNOZZI L,LOPALCO G,GUERRIERO S,et al.Efficacy and safety of adalimumab in Behet’s disease-related uveitis:a multicenter retrospective observational study［J］.Clin Rheumatol,2017,36:183-189.
［38］　杨培增.葡萄膜炎诊断与治疗［M］.北京：人民卫生出版社,2009:754.
YANG PZ.Diagnosis and treatment of uveitis［M］.Beijing:People’s Medical Publishing House,2009:754.
［39］　BODAGHI B,TOUITOU V,FARDEAU C,CHAPELON C,LEHOANG P.Ocular sarcoidosis［J］.Presse Med,2012,41(6 Pt 2):e349-354.
［40］　ERCKENS R J,MOSTARD R L,WIJNEN P A,SCHOUTEN J S,DRENT M.Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis［J］.Graefes Arch Clin Exp Ophthalmol,2012,250(5):713-720.
［41］　YANG P,WAN W,DU L,ZHOU Q,QI J,LIANG L,et al.Clinical features of HLA-B27-positive acute anterior uveitis with or without ankylosing spondylitis in a Chinese cohort［J］.Br J Ophthalmol,2018,102(2):215-219.
［42］　BALEVIC S J,RABINOVICH C E.Profile of adalimumab and its potential in the treatment of uveitis［J］.Drug Des Devel Ther,2016,10:2997-3003.
［43］　SIMONINI G,TADDIO A,CATTALINI M,CAPUTO R,DE LIBERO C,NAVIGLIO S,et al.Prevention of flare recurrences in childhood-refractory chronic uveitis:an open-label comparative study of adalimumab versus infliximab［J］.Arthritis Care Res (Hoboken),2011,63(4):612-618.
［44］　HAMAM R N,BARIKIAN A W,ATONIOS R S,ABDULAAL M R,ALAMEDDINE R M,EL MOLLAYESS G,et al.Intravitreal adalimumab in active noninfectious uveitis:a pilot study［J］.Ocul Immunol Inflamm,2016,24(3):319-326.
［45］　NESTOROV I.Clinical pharmacokinetics of TNF antagonists:how do they differ?［J］.Semin Arthritis Rheum,2005,34(5 Suppl 1):12-18.
［46］　TRACEY D,KLARESKOG L,SASSO E H,SALFEID J G,TAK P P.Tumor necrosis factor antagonist mechanisms of action:a comprehensive review［J］.Pharmacol Ther,2008,117(2):244-279.
［47］　ZANNIN M E,BIEOLO C,GERLONI V M,MISEROCCHI E,PONTIKAKI I,PAROLI M P,et al.Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis:1-year follow up data from the Italian Registry［J］.J Rheumatol,2013,40(1):74-79.
［48］　SCHIMELING H,MINDEN K,FOEIDVARI I,GANSER G,HOSPACH T,HORNEFF G.Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis:the German Biologics JIA Registry［J］.Arthritis Rheumatol,2014,66(9):2580-2589.
［49］　RAMANAN A V,DICK A D,JONES A P,FRISWELL M,BAGULEY E,MAY K,et al.Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis［J］.N Engl J Med,2017,376(17):1637-1646.
［50］　SEVE P,VARRON L,BROUSSOLLE C,DENIS P,KODJIKIAN L.Sarcoidrelated uveitis occurring during adalimumab therapy［J］.Ocul Immunol Inflamm,2012,20(1):59-60.

相似文献/References:

[1]唐耀冰 陈桂英 王晓艳 侯明佳.玻璃体内注射Infliximab治疗大鼠葡萄膜炎的实验研究[J].眼科新进展,2013,33(7):000.
[2]黄云云 罗予 张金嵩 魏丽娟.外伤性兔眼内炎房水中肿瘤坏死因子-α、白细胞介素-1β及中性粒细胞趋化因子-1的相对含量变化及意义[J].眼科新进展,2013,33(8):000.
[3]杨萍 孙书明 李晓鹏.辛伐他汀对糖尿病视网膜病变和炎症因子的影响[J].眼科新进展,2013,33(8):000.
[4]付馨余,邹文进,喻谦,等.多西环素对碱烧伤大鼠角膜组织中IL-1和TNF-α表达的影响[J].眼科新进展,2014,34(10):915.[doi:10.13389/j.cnki.rao.2014.0253]
[5]张运江,俞方良,刘淼,等.兔眼内窥镜下睫状体光凝联合白内障超声乳化手术对房水成分的影响[J].眼科新进展,2014,34(10):918.[doi:10.13389/j.cnki.rao.2014.0254]
[6]吴利安,王从毅,杨新光,等. 骨髓间充质干细胞移植对兔碱烧伤角膜新生血管形成的抑制作用[J].眼科新进展,2015,35(7):623.[doi:10.13389/j.cnki.rao.2015.0169]
　WU Li-An,WANG Cong-Yi,YANG Xin-Guang,et al. Inhibitive effects of bone marrow stem cells on corneal neovascularization in rabbit with corneal alkali burn[J].Recent Advances in Ophthalmology,2015,35(3):623.[doi:10.13389/j.cnki.rao.2015.0169]
[7]翟红艳,王亚娇. 趋化素、肿瘤坏死因子-α与2型糖尿病视网膜病变的相关性[J].眼科新进展,2015,35(7):667.[doi:10.13389/j.cnki.rao.2015.0182]
　ZHAI Hong-Yan,WANG Ya-Jiao. Correlation analysis of chemerin , TNF-α with type 2 diabetic retinopathy[J].Recent Advances in Ophthalmology,2015,35(3):667.[doi:10.13389/j.cnki.rao.2015.0182]
[8]周赟,刘宁宁,万超,等.β-榄香烯对糖尿病大鼠视网膜中肿瘤坏死因子-α表达的影响[J].眼科新进展,2015,35(12):1129.[doi:10.13389/j.cnki.rao.2015.0309]
　ZHOU Yun,LIU Ning-Ning,WAN Chao,et al.Effects of β-elemene on expression of TNF-α in retina of diabetic rats[J].Recent Advances in Ophthalmology,2015,35(3):1129.[doi:10.13389/j.cnki.rao.2015.0309]
[9]彭玲,蔡伟浩,陆晓和,等.氟他胺诱导干眼模型大鼠角膜和泪腺组织病理变化及TNF-α、IL-1α的表达[J].眼科新进展,2016,36(6):506.[doi:10.13389/j.cnki.rao.2016.0135]
　PENG Ling,CAI Wei-Hao,LU Xiao-He,et al.Pathological changes of cornea and lacrimal glands in dry eye rat model induced by flutamide and expression of TNF-α and IL-1α[J].Recent Advances in Ophthalmology,2016,36(3):506.[doi:10.13389/j.cnki.rao.2016.0135]
[10]韩梦雨,金明,王志军.炎性细胞因子与新生血管性眼病[J].眼科新进展,2017,37(11):1088.[doi:10.13389/j.cnki.rao.2017.0275]
　HAN Meng-Yu,JIN Ming,WANG Zhi-Jun.Inflammatory cytokines in neovascular eye diseases[J].Recent Advances in Ophthalmology,2017,37(3):1088.[doi:10.13389/j.cnki.rao.2017.0275]

备注/Memo

备注/Memo:
国家自然科学基金资助（编号：81570859、81670878）
更新日期/Last Update: 2021-03-05